Immune cells injected into liver or veins to fight advanced melanoma
NCT ID NCT07183852
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests whether immune cells taken from a patient's own tumor (TIL) can be safely given directly into the liver or through a vein to fight metastatic melanoma. 18 adults with advanced uveal or cutaneous melanoma that has spread will receive TIL along with chemotherapy and interleukin-2. The main goal is to check safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous tumor infiltrating lymphocytes (TIL), melphalan, interleukin-2
- What this could lead to
- If it works, this could point toward a new way to treat metastatic melanoma that has spread to the liver or other organs.
- What could go wrong
- This is a very early (Phase 1) safety trial with only 18 people. It may not shrink tumors, and side effects from chemotherapy and immune activation could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo tame a rare eye cancer that has spread?
- Can a new drug shrink Hard-to-Treat eye cancer?
- Double immunotherapy plus liver blockade targets eye cancer that spreads
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Could a Gut-Focused drug revive immunotherapy for tough melanomas?
- Blood test aims to spot hidden cancer cells in 9 tumor types